MEDX:NSD-Horizon Kinetics Medical ETF (USD)

ETF | Others |

Last Closing

USD 29.1755

Change

+0.43 (+1.48)%

Market Cap

USD 0.02B

Volume

182.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
QQQM Invesco NASDAQ 100 ETF

-1.50 (-0.73%)

USD 34.13B
IBIT iShares Bitcoin Trust

-0.45 (-1.09%)

USD 26.51B
ACWI iShares MSCI ACWI ETF

-0.53 (-0.44%)

USD 19.47B
JEPQ JPMorgan Nasdaq Equity Premium..

-0.18 (-0.32%)

USD 17.54B
CGABL The Carlyle Group Inc. 4.625% ..

-0.03 (-0.15%)

USD 16.14B
NVDL GraniteShares 1.5x Long NVDA D..

-2.06 (-2.67%)

USD 6.01B
TBIL Rbb Fund Inc - Us Treasury 3 M..

N/A

USD 4.33B
USCL iShares Climate Conscious & Tr..

-0.25 (-0.36%)

USD 2.36B
PABU iShares Paris-Aligned Climate ..

-0.15 (-0.23%)

USD 2.10B
IBTF iShares iBonds Dec 2025 Term T..

+0.01 (+0.04%)

USD 2.09B

ETFs Containing MEDX

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.46% 57% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.46% 54% F 61% D-
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.02B 31% F 16% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector